Posted in | News | Materials Science

Medical Technology Companies to Benefit from Picosun Biocompatible Materials

ESPOO, Finland, 23 of November 2021 – Picosun Group has launched a Medical Materials Library consisting of over ten materials intended for medical-related coating and encapsulation with Atomic Layer Deposition (ALD). ALD coatings are ultra-thin, and they guarantee hermetic encapsulation of virtually any implanted device.

The materials library is a reflection of over six years extensive research and development that shows ALD can render biocompatibility to a substrate coated with Picosun library materials. Biocompatibility tests were carried out according to ISO standards in accredited third-party laboratories. The performed tests included for example cytotoxicity, antimicrobial activity, skin irritation or sensitization, hemocompatibility, bacterial endotoxins, bioburden and sterilization residuals. From the tested materials Picosun is able to design tens of different types of end materials according to customer needs.

ALD technology provides dimensionless coating thus enabling miniaturization of components and devices in the field of electronic implants. Antibacterial function together with excellent barrier properties and outstanding corrosion resistance pave the way for using the materials both in electronic and orthopedic implants and show high potential in pharmaceutical packaging. The superior film uniformity and conformality ensure a pinhole-free coverage over even the smallest details of the device.

“The demonstrated results show the undisputable opportunities ALD offers to the medical sector already today. While the basic surgical principles and technologies have remained the same for decades, now ALD enables unforeseen applications potentially improving patient safety and cost-effectiveness by extending implant durability and reducing adverse effects”, says Niku Oksala, professor of surgery at Tampere University and medical advisor for Picosun.

“Picosun’s Medical Materials Library targeted to the medical device manufacturer segment reflects the innovative spirit of the company. I’m really excited over the fact that we are able to flexibly design tailored encapsulations according to our customers’ needs. I’m especially proud of our medical customers and partners who are already in pre-clinical and clinical trials with their ALD coated devices”, says Juhani Taskinen, Vice President, Medical Business Area of Picosun Group.

More information:
Juhani Taskinen
Vice President, Medical Business Area, Picosun Group
Tel: +358 50 4066 957
Email: [email protected]
www.picosun.com

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Picosun Oy. (2021, November 23). Medical Technology Companies to Benefit from Picosun Biocompatible Materials. AZoM. Retrieved on April 12, 2024 from https://www.azom.com/news.aspx?newsID=57429.

  • MLA

    Picosun Oy. "Medical Technology Companies to Benefit from Picosun Biocompatible Materials". AZoM. 12 April 2024. <https://www.azom.com/news.aspx?newsID=57429>.

  • Chicago

    Picosun Oy. "Medical Technology Companies to Benefit from Picosun Biocompatible Materials". AZoM. https://www.azom.com/news.aspx?newsID=57429. (accessed April 12, 2024).

  • Harvard

    Picosun Oy. 2021. Medical Technology Companies to Benefit from Picosun Biocompatible Materials. AZoM, viewed 12 April 2024, https://www.azom.com/news.aspx?newsID=57429.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.